1. Home
  2. IBRX vs ROAD Comparison

IBRX vs ROAD Comparison

Compare IBRX & ROAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.35

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Logo Construction Partners Inc.

ROAD

Construction Partners Inc.

HOLD

Current Price

$123.06

Market Cap

6.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
ROAD
Founded
2014
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Engineering & Construction
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.4B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
IBRX
ROAD
Price
$7.35
$123.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$12.57
$127.80
AVG Volume (30 Days)
11.7M
584.5K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
38.71
40.46
EPS
N/A
0.47
Revenue
$113,288,000.00
$785,679,000.00
Revenue This Year
$88.59
$27.79
Revenue Next Year
$131.15
$10.29
P/E Ratio
N/A
$270.32
Revenue Growth
668.31
0.31
52 Week Low
$1.95
$93.22
52 Week High
$12.43
$151.00

Technical Indicators

Market Signals
Indicator
IBRX
ROAD
Relative Strength Index (RSI) 51.85 57.28
Support Level $6.69 $105.60
Resistance Level $8.54 $127.93
Average True Range (ATR) 0.40 5.26
MACD 0.04 1.98
Stochastic Oscillator 89.02 84.30

Price Performance

Historical Comparison
IBRX
ROAD

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About ROAD Construction Partners Inc.

Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.

Share on Social Networks: